Log in to search using one of your social media accounts:


Reducing avoidable hospital based care: re-thinking out of hospital clinical pathways

This report is intended as a guide for all stakeholders to improve clinical pathways and develop models of care that are less dependent on acute hospitals. Its recommendations are relevant to both acute and long term condition pathways. The report provides a detailed guide to managing acute symptoms and acute conditions out of hospital where safe and appropriate to do so. It also provides detailed guidance on effective common city based pathways for three common long term conditions: heart failure, respiratory conditions and patients living with and beyond cancer.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news

Related Links:

Biolase (NSDQ:BIOL) said this week its CEO Harold Flynn has resigned from the company to pursue other interests, and that current CFO John Beaver will step in to act as interim CEO. The transition will be made immediately, the Irvine, Calif.-based company said. “I would like to thank Harold for the leadership and commitment he has demonstrated over the last three years.  We are grateful for his contributions to product quality and for his steadfast dedication to Biolase.  We thank him for his continued support and wish him all the best in this new phase of his professional career. We are pleased to hav...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Biolase Conventus Orthopaedics Endotronix Inc. Frequency Therapeutics General Electric Henry Schein Inc. mckeonproducts nsfhealthsciencescertification Omnicell Inc. PerkinElmer Inc. personnel-moves Source Type: news
Publication date: Available online 12 April 2018 Source:Journal of Cancer Policy Author(s): Jia Luo, Vinay Prasad In 2013, the US FDA granted pertuzumab (Perjeta, Genentech/Roche) accelerated approval (AA) for the neo-adjuvant treatment of HER2 positive breast cancer. Approval was later extrapolated to the adjuvant setting by the NCCN and many providers. Pertuzumab remains the first and only drug to utilize an improvement in the rate of pathologic complete response (pCR), as the endpoint for regulatory approval. At the time the FDA utilized pCR as the basis for approval, their own analysis had suggested no correlation at ...
Source: Journal of Cancer Policy - Category: Cancer & Oncology Source Type: research
Conclusions: Template matching–based approaches to hospital quality assessment can be enhanced using more granular electronic medical record data.
Source: Medical Care - Category: Health Management Tags: Original Articles Source Type: research
After a median 20 years of follow - up, heart failure not associated with cancer incidence
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Cardiology, Family Medicine, Internal Medicine, Oncology, Journal, Source Type: news
The study found no association between heart failure and incident cancer and is more definitive than prior investigations, but experts say it is premature to abandon the cancer hypothesis in HF.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news
(MedPage Today) -- Up to 3x higher risk of acute heart failure and stroke with co-morbid diabetes, CAD, hypertension
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
The current arsenal of cancer chemotherapy is broad and rapidly expanding and includes conventional cytotoxic agents and targeted and immune-based therapies. As cancer survival rates have improved, the acute and latent cardiotoxicities of chemotherapy have emerged as important contributors to morbidity and mortality in cancer survivors. All chemotherapeutic agents have the potential for cardiac complications, with manifestations ranging from subclinical left ventricular dysfunction and asymptomatic QT prolongation, to congestive heart failure, myocardial ischemia, myocarditis, arrhythmia, and sudden cardiac death. Efforts ...
Source: Cardiology in Review - Category: Cardiology Tags: Review Articles Source Type: research
Gemcitabine is not considered a cardiotoxic agent generally; so far only very few case reports have been reported in the literature on different aspects of cardiac side effects. Here we report a case series of 3 patients who developed congestive cardiac failure, when treated with gemcitabine monotherapy in the adjuvant setting for pancreatic cancers. Adjuvant chemotherapy with gemcitabine has been the standard of care for pancreatic cancer patients after successful surgery since the results of the CONKO-001 and ESPAC3 study were published. Gemcitabine was administered on days 1, 8, and 15 of a 28-day cycle at 1,000 mg/m2. ...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions This is the first clinical trial using direct cardiac injection of cells for the treatment of AIC. If administration of allo-MSCs is found feasible and safe, SENECA will pave the way for larger phase II/III studies with therapeutic efficacy as the primary outcome.
Source: American Heart Journal - Category: Cardiology Source Type: research
A UCLA-led team has received a five-year, $8.4 million award from the Patient-Centered Outcomes Research Institute to develop effective approaches to improve advance care planning for seriously ill patients treated in primary care clinics.The award, one of seven granted nationally by the research institute, an independent nonprofit, nongovernmental organization, is intended to fund a research project that addresses the needs of both patients and caregivers.UCLADr. Neil WengerUCLA, in collaboration with UC San Francisco and UC Irvine, will compare three planning approaches that could be used in primary care clinics among pe...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
More News: Cancer | Cancer & Oncology | Cardiology | Health | Heart | Heart Failure | Hospitals | Respiratory Medicine